205 related articles for article (PubMed ID: 11094065)
41. Immunohistochemical detection of DNA topoisomerase IIalpha, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer.
Kreisholt J; Sorensen M; Jensen PB; Nielsen BS; Andersen CB; Sehested M
Br J Cancer; 1998 May; 77(9):1469-73. PubMed ID: 9652763
[TBL] [Abstract][Full Text] [Related]
42. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition.
Turner JG; Marchion DC; Dawson JL; Emmons MF; Hazlehurst LA; Washausen P; Sullivan DM
Cancer Res; 2009 Sep; 69(17):6899-905. PubMed ID: 19690141
[TBL] [Abstract][Full Text] [Related]
43. Substrate specificity plays an important role in uncoupling the catalytic and scaffolding activities of rat testis DNA topoisomerase IIalpha.
Bakshi R; Galande S; Muniyappa K
J Biomol Struct Dyn; 2001 Apr; 18(5):749-60. PubMed ID: 11334111
[TBL] [Abstract][Full Text] [Related]
44. 2-[4-(7-chloro-2-quinoxalinyloxyphenoxy]-propionic acid (XK469), an inhibitor of topoisomerase (Topo) IIbeta, up-regulates Topo IIalpha and enhances Topo IIalpha-mediated cytotoxicity.
Mensah-Osman EJ; Al-Katib AM; Wu HY; Osman NI; Mohammad RM
Mol Cancer Ther; 2002 Dec; 1(14):1321-6. PubMed ID: 12516965
[TBL] [Abstract][Full Text] [Related]
45. Smurf2-Mediated Stabilization of DNA Topoisomerase IIα Controls Genomic Integrity.
Emanuelli A; Borroni AP; Apel-Sarid L; Shah PA; Ayyathan DM; Koganti P; Levy-Cohen G; Blank M
Cancer Res; 2017 Aug; 77(16):4217-4227. PubMed ID: 28611047
[TBL] [Abstract][Full Text] [Related]
46. Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process.
Whitacre CM; Zborowska E; Gordon NH; Mackay W; Berger NA
Cancer Res; 1997 Apr; 57(8):1425-8. PubMed ID: 9108439
[TBL] [Abstract][Full Text] [Related]
47. Casein kinase II stabilizes the activity of human topoisomerase IIalpha in a phosphorylation-independent manner.
Redwood C; Davies SL; Wells NJ; Fry AM; Hickson ID
J Biol Chem; 1998 Feb; 273(6):3635-42. PubMed ID: 9452492
[TBL] [Abstract][Full Text] [Related]
48. Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha.
Patel S; Jazrawi E; Creighton AM; Austin CA; Fisher LM
Mol Pharmacol; 2000 Sep; 58(3):560-8. PubMed ID: 10953049
[TBL] [Abstract][Full Text] [Related]
49. Salicylate, a catalytic inhibitor of topoisomerase II, inhibits DNA cleavage and is selective for the α isoform.
Bau JT; Kang Z; Austin CA; Kurz EU
Mol Pharmacol; 2014 Feb; 85(2):198-207. PubMed ID: 24220011
[TBL] [Abstract][Full Text] [Related]
50. Effects of thiols on topoisomerase-II alpha activity and cell cycle progression.
Grdina DJ; Murley JS; Roberts JC
Cell Prolif; 1998; 31(5-6):217-29. PubMed ID: 9925989
[TBL] [Abstract][Full Text] [Related]
51. Acquisition of multiple copies of a mutant topoisomerase IIalpha allele by chromosome 17 aneuploidy is associated with etoposide resistance in human melanoma cell lines.
Campain JA; Slovak ML; Schoenlein PV; Popescu NC; Gottesman MM; Pastan I
Somat Cell Mol Genet; 1995 Nov; 21(6):451-71. PubMed ID: 8600572
[TBL] [Abstract][Full Text] [Related]
52. Association of human DNA topoisomerase IIalpha with mitotic chromosomes in mammalian cells is independent of its catalytic activity.
Mo YY; Beck WT
Exp Cell Res; 1999 Oct; 252(1):50-62. PubMed ID: 10502399
[TBL] [Abstract][Full Text] [Related]
53. DNA Topoisomerase IIα contributes to the early steps of adipogenesis in 3T3-L1 cells.
Jacobsen RG; Mazloumi Gavgani F; Mellgren G; Lewis AE
Cell Signal; 2016 Oct; 28(10):1593-603. PubMed ID: 27404349
[TBL] [Abstract][Full Text] [Related]
54. Effects of wild-type p53 expression on the quantity and activity of topoisomerase IIalpha and beta in various human cancer cell lines.
Hochhauser D; Valkov NI; Gump JL; Wei I; O'Hare C; Hartley J; Fan J; Bertino JR; Banerjee D; Sullivan DM
J Cell Biochem; 1999 Nov; 75(2):245-57. PubMed ID: 10502297
[TBL] [Abstract][Full Text] [Related]
55. ICRF-193, a catalytic inhibitor of DNA topoisomerase II, inhibits re-entry into the cell division cycle from quiescent state in mammalian cells.
Hossain MS; Akimitsu N; Takaki T; Hirai H; Sekimizu K
Genes Cells; 2002 Mar; 7(3):285-94. PubMed ID: 11918672
[TBL] [Abstract][Full Text] [Related]
56. Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint.
Kozuki T; Chikamori K; Surleac MD; Micluta MA; Petrescu AJ; Norris EJ; Elson P; Hoeltge GA; Grabowski DR; Porter ACG; Ganapathi RN; Ganapathi MK
Nucleic Acids Res; 2017 Jun; 45(10):5995-6010. PubMed ID: 28472494
[TBL] [Abstract][Full Text] [Related]
57. Expression of topoisomerase IIalpha in the G0/G1 cell cycle phase of fresh leukemic cells.
Uggla B; Möllgård L; Ståhl E; Mossberg LL; Karlsson MG; Paul C; Tidefelt U
Leuk Res; 2001 Nov; 25(11):961-6. PubMed ID: 11597731
[TBL] [Abstract][Full Text] [Related]
58. Transfection of human topoisomerase II alpha into etoposide-resistant cells: transient increase in sensitivity followed by down-regulation of the endogenous gene.
Asano T; An T; Mayes J; Zwelling LA; Kleinerman ES
Biochem J; 1996 Oct; 319 ( Pt 1)(Pt 1):307-13. PubMed ID: 8870683
[TBL] [Abstract][Full Text] [Related]
59. Catalytic inhibition of DNA topoisomerase IIalpha by sodium azide.
Ju R; Mao Y; Glick MJ; Muller MT; Snyder RD
Toxicol Lett; 2001 Apr; 121(2):119-26. PubMed ID: 11325562
[TBL] [Abstract][Full Text] [Related]
60. Upregulation of topoisomerase IIalpha expression in advanced gallbladder carcinoma: a potential chemotherapeutic target.
Washiro M; Ohtsuka M; Kimura F; Shimizu H; Yoshidome H; Sugimoto T; Seki N; Miyazaki M
J Cancer Res Clin Oncol; 2008 Jul; 134(7):793-801. PubMed ID: 18204862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
